IL298216A - Egfr tkis for use in the treatment of non-small cell lung cancer - Google Patents

Egfr tkis for use in the treatment of non-small cell lung cancer

Info

Publication number
IL298216A
IL298216A IL298216A IL29821622A IL298216A IL 298216 A IL298216 A IL 298216A IL 298216 A IL298216 A IL 298216A IL 29821622 A IL29821622 A IL 29821622A IL 298216 A IL298216 A IL 298216A
Authority
IL
Israel
Prior art keywords
egfr tki
egfr
generation
acceptable salt
tki
Prior art date
Application number
IL298216A
Other languages
English (en)
Hebrew (he)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL298216A publication Critical patent/IL298216A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL298216A 2020-05-27 2021-05-26 Egfr tkis for use in the treatment of non-small cell lung cancer IL298216A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063030372P 2020-05-27 2020-05-27
PCT/EP2021/063992 WO2021239786A1 (en) 2020-05-27 2021-05-26 Egfr tkis for use in the treatment of non-small cell lung cancer

Publications (1)

Publication Number Publication Date
IL298216A true IL298216A (en) 2023-01-01

Family

ID=76181131

Family Applications (1)

Application Number Title Priority Date Filing Date
IL298216A IL298216A (en) 2020-05-27 2021-05-26 Egfr tkis for use in the treatment of non-small cell lung cancer

Country Status (14)

Country Link
US (3) US20210369709A1 (enExample)
EP (1) EP4157267B1 (enExample)
JP (1) JP2023529812A (enExample)
KR (1) KR20230017830A (enExample)
CN (2) CN115776889A (enExample)
AU (1) AU2021279171A1 (enExample)
BR (1) BR112022023519A2 (enExample)
CA (1) CA3183434A1 (enExample)
DK (1) DK4157267T3 (enExample)
FI (1) FI4157267T3 (enExample)
IL (1) IL298216A (enExample)
MX (1) MX2022014903A (enExample)
TW (1) TW202216149A (enExample)
WO (1) WO2021239786A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022526159A (ja) 2019-03-29 2022-05-23 アストラゼネカ・アクチエボラーグ 非小細胞肺がんの治療に使用するためのオシメルチニブ
US12649792B2 (en) 2019-05-06 2026-06-09 Brown University Bispecific antibodies against CHI3L1 and PD1 with enhanced T cell-mediated cytotoxic effects on tumor cells
WO2024059962A1 (en) * 2022-09-19 2024-03-28 Shanghai Allist Pharmaceuticals Co., Ltd. Pharmaceutical composition and use thereof
WO2024118611A2 (en) * 2022-11-28 2024-06-06 Brown University Treatment of epidermal growth factor receptor mutant non-small cell lung cancer
CN117298116A (zh) * 2023-08-08 2023-12-29 江苏晨泰医药科技有限公司 盐酸佐利替尼制剂
CN121177212B (zh) * 2025-11-25 2026-03-03 中南大学湘雅二医院 一种用于治疗egfr突变非小细胞肺癌脑膜转移的药物、应用、药盒及药物的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10063435A1 (de) 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
HRP20110958T1 (hr) 2004-05-06 2012-01-31 Warner-Lambert Company Llc 4-fenilaminokinazolin-6-ilamidi
DK3686193T3 (da) * 2011-07-27 2022-05-30 Astrazeneca Ab 2-(2,4,5-substitueret anilino)pyrimidinforbindelser
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
LT2964638T (lt) 2013-03-06 2017-12-27 Astrazeneca Ab Epidermio augimo faktoriaus receptoriaus aktyvinančių mutacijų formų chinazolino inhibitoriai
ES3069593T3 (en) 2013-08-23 2026-06-09 Neupharma Inc Quinazolin-8-yl derivatives for use in methods of treating melanoma, non-small cell lung cancer, thyroid cancer, ovarian cancer, or colon cancer
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
US20170166598A1 (en) 2014-05-13 2017-06-15 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
CN105315259B (zh) 2014-07-29 2018-03-09 上海艾力斯医药科技有限公司 吡啶胺基嘧啶衍生物、其制备方法及应用
EP3205650B1 (en) 2014-10-11 2021-08-04 Shanghai Hansoh Biomedical Co., Ltd. Egfr inhibitor, and preparation and application thereof
EP3929190B1 (en) 2014-10-13 2024-12-25 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities
CN111170998B (zh) 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
AU2015360360B2 (en) 2014-12-11 2020-06-25 Beta Pharma (Shanghai) Co., Ltd. Substituted 2-anilinopyrimidine derivatives as EGFR modulators
CN107614503B (zh) 2015-04-29 2020-03-10 广东众生药业股份有限公司 稠环或三环芳基嘧啶化合物用作激酶抑制剂
EP3661519A1 (en) * 2017-08-03 2020-06-10 Novartis AG Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor

Also Published As

Publication number Publication date
JP2023529812A (ja) 2023-07-12
CA3183434A1 (en) 2021-12-02
AU2021279171A1 (en) 2023-02-02
EP4157267A1 (en) 2023-04-05
CN115776889A (zh) 2023-03-10
DK4157267T3 (da) 2026-08-03
US20210369709A1 (en) 2021-12-02
WO2021239786A1 (en) 2021-12-02
KR20230017830A (ko) 2023-02-06
US20240423978A1 (en) 2024-12-26
US20250325543A1 (en) 2025-10-23
MX2022014903A (es) 2023-01-04
EP4157267B1 (en) 2026-07-08
CN122376595A (zh) 2026-07-14
TW202216149A (zh) 2022-05-01
FI4157267T3 (fi) 2026-08-12
BR112022023519A2 (pt) 2022-12-20

Similar Documents

Publication Publication Date Title
US20250325543A1 (en) EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL LUNG CANCER
JP6949726B2 (ja) Ｅｇｆｒ変異癌を治療する方法
US12465608B2 (en) Osimertinib for use in the treatment of non-small cell lung cancer
KR102490547B1 (ko) 퀴놀린 유도체로 갑상선암을 치료하기 위한 방법과 용도 및 갑상선암을 치료하기 위한 약학적 조성물
JP2024509823A (ja) アムセネストラントおよびパルボシクリブによる乳がんの処置
KR20250013187A (ko) 니로가세스타트를 사용한 치료
JP2017521468A (ja) 組み合わせ療法
US20250057847A1 (en) Plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancer
EP4093394A1 (en) Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
WO2023168036A1 (en) Method of treatment including kras g12c inhibitors and shp2 inhibitors
US20210161897A1 (en) Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
JP7841087B2 (ja) Ｍｅｔ受容体チロシンキナーゼ阻害剤を含む薬物の組み合わせ及びその使用
AU2023303878A1 (en) Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer
WO2022191870A1 (en) Treating cancer in patient having co-occurring genetic alteration in fgfr2 and a cancer driver gene
EA052374B1 (ru) Осимертиниб для применения в лечении немелкоклеточного рака легкого
EA051679B1 (ru) Комбинации лекарственных средств, содержащие ингибиторы тирозинкиназы рецептора met, и их применение